Overview of CNS Neuropharmaceuticals
作者： Tauser Roxana-Georgiana , Antohe Dan-Stefan
DOI: 10.1002/9780470571224.PSE456
关键词: Neuroproteomics 、 Biology 、 Antisense oligonucleotides 、 Drug 、 Drug discovery 、 Drug design 、 Targeted drug delivery 、 Drug development 、 Neuroscience
摘要: The advances in the molecular neurosciences during “the decade of brain” conjunction with new genomic and proteomic sciences have radically changed paradigm central nervous system (CNS) drug design development. classical, chemistry-based small-molecule discovery has been broadened by twenty-first century biology-driven large-molecule neuropharmaceuticals: peptides, recombinant proteins, monoclonal antibodies, antisense oligonucleotides, gene therapy. As this chapter will discuss, however, despite progress field neuroproteomics rational strategies, there is still a high failure rate candidates later stages projects consequently an unsatisfied demand for novel neurotherapeutic neurodiagnostic medicines. Therefore, CNS targeting must be merged early development process order to obtain neuropharmaceuticals active brain following systemic administration. Keywords: neuropharmaceuticals; central (CNS); neuroproteomics; rational
sci-hub.st 参考文章(224)
F. I. Braginskaya, O. M. Zorina, N. P. Pal'mina, V. D. Gaintseva, E. B. Burlakova, N. D. Selezneva, I. V. Kolykhalov, S. I. Gavrilova, Some blood biochemistry parameters during the cholinergic treatment of Alzheimer's disease. Neuroscience and Behavioral Physiology. ,vol. 31, pp. 457- 461 ,(2001) , 10.1023/A:1010405115973
Mutay Aslan, Tomris Ozben, Reactive Oxygen and Nitrogen Species in Alzheimers Disease Current Alzheimer Research. ,vol. 1, pp. 111- 119 ,(2004) , 10.2174/1567205043332162
Adam Doble, The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacology & Therapeutics. ,vol. 81, pp. 163- 221 ,(1999) , 10.1016/S0163-7258(98)00042-4
Zoltán Benyó, Christoph Görlach, Szabolcs Hortobágyi, Tibor Hortobágyi, Neuronal nitric oxide synthase inhibitor has a neuroprotective effect in a rat model of brain injury. Restorative Neurology and Neuroscience. ,vol. 17, pp. 71- 76 ,(2000)
Eliseo O. Campos, Alejandra Alvarez, Nibaldo C. Inestrosa, Brain acetylcholinesterase promotes amyloid-beta-peptide aggregation but does not hydrolyze amyloid precursor protein peptides. Neurochemical Research. ,vol. 23, pp. 135- 140 ,(1998) , 10.1023/A:1022416505725
Albert Enz, Rene Amstutz, H. Boddeke, G. Gmelin, J. Malanowski, BRAIN SELECTIVE-INHIBITION OF ACETYLCHOLINESTERASE - A NOVEL-APPROACH TO THERAPY FOR ALZHEIMERS-DISEASE Progress in Brain Research. ,vol. 98, pp. 431- 438 ,(1993) , 10.1016/S0079-6123(08)62429-2
Brenda Kwak, Flore Mulhaupt, Samir Myit, François Mach, Statins as a newly recognized type of immunomodulator Nature Medicine. ,vol. 6, pp. 1399- 1402 ,(2000) , 10.1038/82219
Amy K. Stout, Heather M. Raphael, Beatriz I. Kanterewicz, Eric Klann, Ian J. Reynolds, Glutamate-induced neuron death requires mitochondrial calcium uptake. Nature Neuroscience. ,vol. 1, pp. 366- 373 ,(1998) , 10.1038/1577
Dave Morgan, David M. Diamond, Paul E. Gottschall, Kenneth E. Ugen, Chad Dickey, John Hardy, Karen Duff, Paul Jantzen, Giovanni DiCarlo, Donna Wilcock, Karen Connor, Jaime Hatcher, Caroline Hope, Marcia Gordon, Gary W. Arendash, A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. ,vol. 408, pp. 982- 985 ,(2000) , 10.1038/35050116